

Immunopathogenesis of Psoriasis and Pharmacological Perspectives

STEFANIA LOFFREDO, FABIO AYALA, GIANCARLO MARONE, GABRIELE DELFINO,
SAVERIO STRANGES, and GIANNI MARONE

ABSTRACT. Psoriasis is a chronic inflammatory disorder resulting from a combination of genetic and environmental factors, although the precise causal agents have not yet been identified. The immune system has a major role in the development of psoriasis, and the possibility exists that self antigens, antigens from microbial agents, or microbial superantigens initiate a vigorous immune response. Different subsets of T lymphocytes and dendritic cells, mast cells, and granulocytes participate in the pathogenesis; and several cytokines and chemokines have been identified in tissue lesions. Tumor necrosis factor- α , interleukin 17 (IL-17), and IL-23 are key cytokines with important pathogenetic roles in psoriasis. Angiogenesis is a prominent early event in lesional psoriatic skin. Potential targets in the treatment of this disorder include biologic agents aimed at blockade of cytokines, chemokines, and angiogenic factors. (J Rheumatol 2009;36 Suppl 83:9-11; doi:10.3899/jrheum.090210)

Key Indexing Terms:

IMMUNITY

PSORIASIS

CELLS

Psoriasis results from a combination of genetic and environmental factors. Two to three percent of the population worldwide is affected by psoriasis. Although the etiology of the disease remains unknown, many factors trigger or exacerbate psoriasis, including bacterial pharyngitis, stress, HIV-1, and various medications. The disease is characterized by proliferation of the epidermis, and the immune system has a prominent role in its development¹.

In psoriatic skin lesions there is a mixture of innate immune cells [neutrophils, mast cells, dendritic antigen presenting cells (APC), and natural killer T cells (NKT)], adaptive immune cells (CD4+ and CD8+ T lymphocytes), and inflammatory infiltrate. There are 2 subsets of CD8+ T cells: an epidermal homing subset expressing integrin (CD103) and a subset that remains in the dermis, in transit either to or from the epidermis. The antigen specificity of skin infiltrating T cells has not yet been identified. These cells may recognize self (epidermal or keratinocyte derived) polypeptides, microbial antigens, or superantigens^{1,2}. Antigen recognition by T cells requires that mature, professional APC process polypeptides, load them onto major histocompatibility complex class I or II

molecules, and ultimately present the processed peptides to the T cells together with a multitude of signals. Conjugation of the T cell and the APC and the formation of the immunologic synapse results in complete activation of T cells and the secretion of cytokines that are found in psoriatic lesions [interferon- γ (IFN- γ), tumor necrosis factor- α (TNF- α)].

The presence of dendritic cell (DC) subsets, whose frequency is normally very low in peripheral blood, together with activated T cells, constitutes a fundamental aspect of the disease process, because *in situ* recruitment of both cell types drives the chronic T cell activation in skin lesions. Thus, identification of this cell network within the psoriatic lesions is a fundamental aspect of how the immune system functions (or dysfunctions) in psoriasis.

Th17 cells are a distinct lineage of proinflammatory T helper cells that are essential for autoimmune diseases. In humans, commitment to the Th17 lineage is dependent on IL-1 β and IL-23^{3,4}. Th17 cells synthesize IL-17A, IL-17F, IL-22, IL-26, and IFN- γ and express transcription factor retinoid orphan receptor gamma T and CD161. Psoriatic skin lesions contain IL-23-producing DC⁵ and IL-17A, which is responsible for tissue neutrophilia. IL-23 consists of a unique p19 subunit coupled to the p40 subunit of IL-12. Interestingly, a fully human monoclonal antibody that binds to p40, neutralizing the effects of both IL-23 and IL-12, is effective in the treatment of psoriasis⁶.

Several subsets of T lymphocytes have immunoregulatory functions. For example, a CD4+ T cell subset that constitutively expresses CD25 has been termed the T-regulatory cell (T_{reg}). These cells suppress immune responses and prevent the development of autoimmune diseases⁷. T_{reg} cells can suppress the activities of CD4+ and CD8+

From the Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.

S. Loffredo, PhD, Division of Clinical Immunology and Allergy and Center for Basic and Clinical Immunology Research, University of Naples Federico II; F. Ayala, MD, Division of Dermatology, Department of Systemic Pathology, University of Naples Federico II; GC. Marone; G. Delfino, MD; S. Stranges, MD; G. Marone, MD, FRCP, Division of Clinical Immunology and Allergy and Center for Basic and Clinical Immunology Research, University of Naples Federico II.

Address correspondence to Dr. G. Marone, Center for Basic and Clinical Immunology Research, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2009. All rights reserved.

Loffredo, et al: Pathogenesis of psoriasis

T cells in a nonantigen-specific manner, both *in vitro* and *in vivo*, through 2 mechanisms: cell contact and suppressive cytokines such as IL-10 and transforming growth factor- β ⁸. Mast cells are essential in inducing T_{reg} cell-dependent peripheral tolerance⁹. Deficient T_{reg} cell activity has been associated with a number of autoimmune conditions. Sugiyama, *et al* demonstrated deficient T_{reg} cell activity in the peripheral blood and in skin lesions of patients with psoriasis¹⁰.

NKT are a subset of T cells¹¹ distinct from NK cells in that they express a T-cell receptor (TCR), but also certain NK receptors such as CD94 and CD161. These cells express a limited TCR repertoire, typically V α 24J α Q and V β 11 in humans, which limits them to recognizing only a narrow spectrum of antigens. NKT recognize glycolipids (α -galactosylceramide or glycosylphosphatidyl inositol) presented in the context of CD1d on the APC, rather than processed polypeptides. The natural ligands for NKT have not been identified, and the definitive role of these cells in psoriasis remains to be fully elucidated¹. A primary abnormality in the lesion of psoriasis is the perivascular accumulation of neutrophils and their influx into the epidermis. Neutrophils can contribute to the hyperproliferation of keratinocytes induced by leukocyte elastase¹².

Human mast cells are usually distributed throughout normal connective tissue and produce a wide array of mediators and cell-cell signaling molecules. This variety may account for the cells' unique features in the immune system¹³. Skin mast cell density is increased in psoriasis¹⁴. Expression of both CD30 and CD30L is upregulated in lesional skin, as is the density of IL-8+ mast cells. Engagement of CD30L on mast cells induces the release of several chemokines [IL-8, monocyte chemoattractant protein-1, and macrophage inflammatory protein 1 β (MIP-1 β)]¹⁴. Corticotropin-releasing hormone (CRH) coordinates the systemic stress response, with repercussions on the inflammatory response. Psoriasis is exacerbated by stress, and mast cells express CRH receptors and synthesize CRH¹⁵. CRH also stimulates secretion of vascular endothelial growth factor-A (VEGF-A) from mast cells through the activation of CRH receptors¹⁶. The expression of VEGF and serum levels of VEGF are related to disease activity¹⁷. Mast cells express several isoforms of VEGF^{1,18,19}, and angiogenesis is critical for psoriasis²⁰. Angiopoietins are the major ligands of the endothelial receptor Tie-2. Angiopoietin 1 (Ang-1) induces Tie-2 signaling and maintains vessel formation, while Ang-2 destabilizes vessels by blocking Tie-2 signaling as an antagonist of Ang-1 and acts with VEGF to initiate angiogenesis²¹. Ang-1 and Ang-2 and Tie-2 expression is upregulated in perivascular regions in lesional psoriatic skin²². Therefore, mast cells, which are closely associated with blood vessels and increase at

angiogenic sites, can contribute to various aspects of angiogenesis¹⁹. Activation of human mast cells leads to the *de novo* synthesis of a wide spectrum of cytokines (e.g., TNF- α , stem cell factor)^{13,23} and chemokines (e.g., IL-8, MIP-1 α)²⁴. Human skin mast cells contain and release TNF- α ²⁵, thus contributing to the local production of TNF- α in psoriasis, and the IL-8 findings might explain the neutrophil infiltration in this disorder. Mast cells in psoriatic skin are strongly positive for IFN- γ ²⁶, thus contributing to Th1 polarization in this disorder. Collectively, these findings provide evidence for the important role of mast cells in the pathogenesis of psoriasis.

The psoriatic plaque contains Th1 type cytokines (IFN- γ , IL-2, and TNF- α)²⁷. APC infiltrating the skin lesions also contribute to the local cytokines, which include IL-18, IL-23, and TNF- α . IL-18 and IL-23 both induce IFN- γ production by Th1 cells. IL-23 is a dominant cytokine in psoriatic plaques^{5,28}. TNF- α is a key proinflammatory cytokine with an important pathogenic role in psoriasis. The central role of TNF- α is confirmed by the therapeutic efficacy of TNF- α -targeting agents (etanercept, infliximab, and adalimumab)¹⁷.

CONCLUSIONS

An intricate network of different cell types interacts to induce chronic inflammation in psoriasis. Advances in understanding the immunopathogenesis of psoriasis have led to improvements in treatment. Targeting the TNF- α /TNF- α R system and IL-12/IL-23 clearly benefits the majority of patients with psoriatic skin lesions. Future challenges include careful monitoring of patients receiving new biologics and investigating the longterm sequelae of chronic inflammatory inhibitors as regards potential risks of infections and neoplasms. In addition, we must carry on working to define the cytokine and chemokine networks operative both upstream and downstream from TNF- α .

REFERENCES

1. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. *J Am Acad Dermatol* 2006;54:S67-80.
2. Loffredo S, Ayala F, Marone GG, Genovese A, Marone G. Immunopathogenesis of psoriasis and psoriatic arthritis and pharmacological perspectives. *Reumatismo* 2007;59:28-39.
3. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. *Nat Immunol* 2007;8:950-7.
4. Cosmi L, De Palma R, Santarasci V, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. *J Exp Med* 2008;205:1903-16.
5. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. *J Exp Med* 2006;203:2577-87.
6. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. *N Engl J Med* 2007;356:580-92.

7. Wraith DC, Nicolson KS, Whitley NT. Regulatory CD4+ T cells and the control of autoimmune disease. *Curr Opin Immunol* 2004;16:695-701.
8. Waldmann H. Immunology: protection and privilege. *Nature* 2006;442:987-8.
9. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T cell tolerance. *Nature* 2006;442:997-1002.
10. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. *J Immunol* 2005;174:164-73.
11. Kay AB. Natural killer T cells and asthma. *N Engl J Med* 2006;354:1186-8.
12. Rogalski C, Meyer Hoffert U, Proksch E, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo. *J Invest Dermatol* 2002;118:49-54.
13. Marone G, Triggiani M, de Paulis A. Mast cells and basophils: friends as well as foes in bronchial asthma? *Trends Immunol* 2005;26:25-31.
14. Fischer M, Harvima IT, Carvalho RF, et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation independent chemokine secretion. *J Clin Invest* 2006;116:2748-56.
15. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin releasing factor and related peptides. *Trends Pharmacol Sci* 2004;25:563-8.
16. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol* 2005;174:7665-75.
17. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. *J Am Acad Dermatol* 2006;54:S85-91.
18. de Paulis A, Prevete N, Fiorentino I, et al. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. *J Immunol* 2006;177:7322.
19. Detoraki A, Staiano RI, Granata F, et al. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic, lymphangiogenic, and proinflammatory effects. *J Allergy Clin Immunol* 2009;123:1142.
20. Detmar MM, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. *J Exp Med* 1994;180:1141-6.
21. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular specific growth factors and blood vessel formation. *Nature* 2000;407:242-8.
22. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. *J Invest Dermatol* 2001;116:713-20.
23. Patella V, Giuliano A, Bouvet JP, Marone G. Endogenous superallergen protein Fv induces IL 4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. *J Immunol* 1998;161:5647-55.
24. Marone G, Triggiani M, Genovese A, de Paulis A. Role of human mast cells and basophils in bronchial asthma. *Adv Immunol* 2005;88:97-160.
25. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. *Proc Natl Acad Sci USA* 1991;88:4220-4.
26. Ackermann L, Harvima IT, Pelkonen J, et al. Mast cells in psoriatic skin are strongly positive for interferon gamma. *Br J Dermatol* 1999;140:624-33.
27. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon gamma, interleukin 2, and tumor necrosis factor alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. *J Invest Dermatol* 1999;113:752-9.
28. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. *J Exp Med* 2004;199:125-30.